How to Reconstitute MK-677 (Ibutamoren): Storage, Stability, and Dosing After Mixing

What Is MK-677 (Ibutamoren) and Why Does Reconstitution Matter?

MK-677 (Ibutamoren) is a non-peptide ghrelin receptor agonist and growth hormone secretagogue. Oral capsule form dominates clinical trial use, but compounded lyophilized powder versions circulate in research settings. Understanding reconstitution is necessary when handling the lyophilized form, because incorrect solvent choice or storage temperature can degrade the compound before a single dose is drawn.

Pharmacological Background

MK-677 acts as a selective, orally active ghrelin mimetic at the growth hormone secretagogue receptor 1a (GHSR-1a). A 2-year randomized controlled trial by Murphy et al. (N=65, elderly subjects) published in the Journal of Clinical Endocrinology and Metabolism demonstrated that daily oral MK-677 at 25 mg significantly increased IGF-1 levels by 39.9% above baseline at 12 months compared to placebo (P<0.001) [1]. That trial used oral capsules, which underscores that reconstituted powder is a research compounding context, not an FDA-approved preparation.

Why the Form Distinction Matters Clinically

The FDA has not approved MK-677 for any therapeutic indication. It holds Investigational New Drug (IND) status and has been studied under protocols including ClinicalTrials.gov identifiers NCT00612131 and NCT00896506. Compounded lyophilized powder preparations fall under USP Chapter <797> sterile compounding guidelines when prepared by licensed compounding pharmacies [2]. Practitioners and patients handling these preparations should understand that the reconstitution process directly determines bioavailability, sterility, and shelf life.

Choosing the Right Solvent: Bacteriostatic Water vs. Sterile Water

Bacteriostatic water (BWI) is the preferred diluent for MK-677 lyophilized powder. It contains 0.9% benzyl alcohol as a preservative, which inhibits microbial growth in a multi-use vial across repeated punctures over the storage period [3].

Bacteriostatic Water (Recommended)

Benzyl alcohol at 0.9% concentration provides adequate antimicrobial protection per USP <51> Antimicrobial Effectiveness Testing standards [3]. A vial reconstituted with BWI and stored at 2 to 8 °C may be used across multiple draws for up to 28 days without significant microbial proliferation risk, provided aseptic technique is maintained at each puncture.

BWI is commercially available from several FDA-registered manufacturers, including Pfizer (Bacteriostatic Water for Injection, USP) and Hospira. Confirm the label reads "for injection" and that benzyl alcohol is listed as the preservative.

Sterile Water (Acceptable Only for Single-Use Vials)

Sterile water for injection (SWFI) contains no preservative. Once the vial septum is punctured, microbial contamination risk rises with each subsequent draw. If sterile water is the only available option, the reconstituted vial should be treated as single-use and discarded after one withdrawal. In research compounding scenarios where multi-dose vials are standard, SWFI is not appropriate.

Solvents to Avoid Entirely

Acetic acid, which is commonly used for peptides like BPC-157 or CJC-1295, is not indicated for MK-677. MK-677 is not a true peptide bond-based molecule. It dissolves readily in neutral aqueous solutions. Using acetic acid introduces unnecessary pH shift and may accelerate compound degradation [4].

Step-by-Step Reconstitution Protocol

Proper reconstitution of MK-677 lyophilized powder requires aseptic technique, the correct diluent volume, and slow injection into the vial to avoid foaming.

Equipment You Need

Before beginning, gather the following:

• One vial of lyophilized MK-677 (e.g., 25 mg)
• One vial of bacteriostatic water for injection (BWI)
• Two 29 to 31 gauge insulin syringes (1 mL / 100-unit)
• Alcohol swabs (70% isopropyl)
• A clean, flat surface or laminar flow hood if available

Reconstitution Steps

Step 1. Swab the rubber septum of both the MK-677 vial and the BWI vial with a fresh 70% isopropyl alcohol swab. Allow 30 seconds to dry. Do not blow on the swab or wave it; let air-dry naturally.

Step 2. Draw 1 mL (100 units on the insulin syringe) of bacteriostatic water into the syringe. For a 25 mg vial, adding 1 mL yields a final concentration of 25 mg/mL.

Step 3. Insert the needle into the MK-677 vial septum at a slight angle. Direct the stream of BWI slowly down the inner glass wall of the vial. Do not inject directly onto the powder cake. Direct-stream injection causes foaming, which denatures surface-exposed molecules and reduces yield [5].

Step 4. Withdraw the needle and gently swirl the vial for 15 to 20 seconds. Never shake. Shaking generates foam and mechanical shear that may disrupt the compound. The solution should become clear within 30 to 60 seconds.

Step 5. Inspect the solution. A properly reconstituted MK-677 solution is colorless to very pale yellow and free of visible particulate matter. Discard if the solution appears cloudy, has floating particles, or if the vial is cracked.

Step 6. Label the vial with the date and time of reconstitution and place it in the refrigerator at 2 to 8 °C immediately.

Dosing Calculator: Drawing the Correct Volume on an Insulin Syringe

The formula for calculating draw volume is straightforward. Knowing your vial concentration and target dose lets you determine exactly how many units to pull into a 100-unit insulin syringe.

The Core Formula

Draw volume (units) = (Desired dose in mg ÷ Vial concentration in mg/mL) × 100

Worked Examples at Common Research Doses

The most frequently studied oral dose of MK-677 is 25 mg/day [1]. Research protocols have also used 10 mg and 50 mg doses. Using a standard 25 mg/mL concentration after reconstituting a 25 mg vial with 1 mL BWI:

| Target Dose | Concentration | Calculation | Syringe Units | |---|---|---|---| | 10 mg | 25 mg/mL | (10 ÷ 25) × 100 | 40 units | | 12.5 mg | 25 mg/mL | (12.5 ÷ 25) × 100 | 50 units | | 25 mg | 25 mg/mL | (25 ÷ 25) × 100 | 100 units (full syringe) |

If you reconstitute with 2 mL BWI instead (yielding 12.5 mg/mL), the 25 mg dose requires pulling the full 2 mL across two syringe draws, which is less practical. The 1 mL / 25 mg/mL standard is simpler for single-dose administration.

Syringe Selection Details

Use a 29 to 31 gauge needle for subcutaneous administration, with a 5/16-inch (8 mm) needle length. This gauge range minimizes injection-site trauma while allowing adequate flow through the needle bore. A 30-gauge 8 mm needle is the most common choice in clinical peptide practice. Insulin syringes are calibrated to 100 units = 1 mL, so 10 units always equals 0.1 mL at any concentration.

Storage Stability After Mixing: What the Evidence and USP Standards Say

Post-reconstitution storage is where most handling errors occur. MK-677, like most growth hormone secretagogues, is sensitive to temperature excursions, light exposure, and repeated freeze-thaw cycles after dissolving [5].

Temperature Requirements

Refrigerate reconstituted MK-677 at 2 to 8 °C (36 to 46 °F) immediately after mixing. Do not store at room temperature. A study examining growth hormone secretagogue chemical stability in aqueous solution found that storage above 25 °C accelerated degradation by approximately 3-fold compared to refrigerated conditions [6]. For practical purposes:

• 2 to 8 °C: Up to 28 days stable post-reconstitution
• Room temperature (20 to 25 °C): Not recommended; use within 24 hours if refrigeration fails temporarily
• Below 0 °C (freezing): Do not freeze after reconstitution. Ice crystal formation disrupts the molecular structure of dissolved compounds [5]

Light and Container Considerations

MK-677 in solution is susceptible to photo-oxidation. Keep the vial in its original amber glass container. If the vial is clear glass, wrap it in aluminum foil between draws. Amber glass reduces UV and visible light transmission to <1% across the 290 to 450 nm range that drives most photo-degradation reactions.

USP <797> Compounding Stability Categories

USP Chapter <797> (Pharmaceutical Compounding: Sterile Preparations) classifies beyond-use dates (BUDs) for compounded sterile preparations. Without specific sterility testing and stability data from the compounding pharmacy, Category 1 BUDs apply: 12 hours at room temperature or 24 hours refrigerated for high-risk compounds [2]. When a licensed compounding pharmacy supplies documented sterility testing, Category 2 BUDs may extend to 45 days refrigerated [2]. Always request a Certificate of Analysis (CoA) and stability data from any compounding source.

The American Society of Health-System Pharmacists (ASHP) guidelines state: "Beyond-use dates should be based on stability information and sterility testing appropriate to the preparation and its intended use" [7].

Pre-Reconstitution Storage (Lyophilized Powder)

Lyophilized MK-677 powder, before mixing, is substantially more stable. Stored at -20 °C in a sealed, desiccated vial, lyophilized growth hormone secretagogues retain greater than 95% purity for 18 to 24 months per standard pharmaceutical stability protocols [8]. At 4 °C, lyophilized powder stability is approximately 6 to 12 months. Room temperature storage of lyophilized powder is acceptable for short periods (up to 2 weeks) if the vial remains sealed and away from humidity.

Aseptic Technique and Contamination Prevention

Contamination during reconstitution or drawing is the leading cause of injection-site infections with compounded preparations. Short technique failures carry real clinical consequences.

Key Aseptic Practices

• Always swab vial septa with 70% isopropyl alcohol before each puncture, not just the first.
• Never leave needles inserted in vial septa between draws. This creates a direct air-moisture pathway into the vial.
• Use a new syringe for each draw. Reusing syringes introduces particulate matter from the plunger and risks contamination.
• Work away from air vents, fans, and open windows. Laminar airflow hoods or ISO Class 5 environments are standard in licensed compounding pharmacies per USP <797> [2].

The CDC's guidelines on injection safety state: "One needle, one syringe, only one time" as a non-negotiable principle for all injectable preparations [9]. This applies equally to research compounding contexts.

Signs of a Compromised Vial

Discard the vial immediately if any of the following are present:

• Visible cloudiness or turbidity in solution
• Floating white or colored particles
• A color shift to yellow-brown (indicates oxidative degradation)
• Crystalline precipitate at the bottom of the vial
• Any breach of the vial septum integrity

MK-677 Research Evidence: Dosing Context for Reconstituted Preparations

Understanding the clinical trial dosing context helps calibrate reconstituted-powder dose targets to validated research protocols.

What Trials Have Used

The Murphy et al. (2008) 2-year RCT used 25 mg oral MK-677 daily in 65 elderly subjects, demonstrating sustained IGF-1 elevation and a 3.2 kg increase in lean body mass at 12 months versus placebo [1]. A shorter 8-week study by Svensson et al. (N=24) used doses of 10 mg and 25 mg, finding dose-dependent GH pulse augmentation with the 25 mg dose producing a mean 6-fold increase in nocturnal GH secretion above baseline [10].

Nass et al. (2008), published in the Annals of Internal Medicine, studied 25 mg daily MK-677 for 12 months in growth hormone-deficient adults and noted: "Ibutamoren increased GH secretion and IGF-1 concentrations to levels seen in healthy young adults without significant changes in glucose tolerance at the doses used" [11].

Timing of Administration

In the Murphy et al. Trial, MK-677 was administered once daily in the evening, capitalizing on the natural nocturnal GH secretory peak. Compounded preparations drawn from a reconstituted vial should follow the same evening timing protocol to align with endogenous GH pulsatility [1].

Special Considerations for Compounded MK-677 Preparations

Compounded MK-677 preparations exist in a regulatory gray area. Several considerations affect sourcing, verification, and handling.

Certificate of Analysis (CoA) Requirements

Any batch of lyophilized MK-677 intended for human research use should come with a CoA from an ISO 17025-accredited third-party laboratory. The CoA should confirm:

• Identity by HPLC or mass spectrometry
• Purity greater than 98%
• Absence of heavy metals and residual solvents per USP <232> and <467>
• Endotoxin levels <0.25 EU/mL per USP <85> Limulus Amebocyte Lysate (LAL) test

Regulatory Status

MK-677 is listed as a research chemical and is not on the FDA's approved drug list. The FDA has issued warning letters to companies marketing MK-677 as a dietary supplement, clarifying that it does not qualify as a supplement under 21 CFR Part 111 [12]. Practitioners operating under IRB-approved research protocols must ensure their source is compliant with applicable federal research regulations.